COST Action "Regenerative Sphincter Therapy" funded
Regenerative Sphincter Therapy (ReST)
Urinary incontinence is a major health burden. For many patients urinary incontinence is associated with progressive degeneration of the muscular tissue. During this process muscle cells die. Novel cell-based therapy for regeneration and improvement of the sphincter muscle can tackle the etiology of incontinence rather than the consequences. But different laboratories use different cell-based sphincter approaches. This COST action, Regenerative Sphincter Therapy (ReST), will endorse a strong interdisciplinary collaboration in academic, clinical, and medical technology with the major aim: build an international board of experts to harmonize cell-based patient therapy methods to lead to an international multi-centre study for approval by the EMA. COST will allow us to reach out to other networks across disciplines to promote pan-European teaching and investigation. COST will contribute not only to the quality of life of patients affected, but in the long run may help to control costs caused by incontinence by providing knowledge on efficacy of various regenerative sphincter therapies.
Start of the action spring 2013